

Sarat Chandarlapaty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9351688/publications.pdf>

Version: 2024-02-01

99
papers

15,504
citations

30070

54
h-index

32842

100
g-index

107
all docs

107
docs citations

107
times ranked

21129
citing authors

#	ARTICLE	IF	CITATIONS
1	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. <i>Cancer Discovery</i> , 2022, 12, 356-371.	9.4	68
2	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. <i>Modern Pathology</i> , 2022, 35, 396-402.	5.5	9
3	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
4	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
5	The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. <i>Cancer Research</i> , 2022, 82, 2269-2280.	0.9	6
6	Recurrent <i>WWTR1</i> S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. <i>Journal of Pathology</i> , 2022, 257, 635-649.	4.5	2
7	Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2655.	1.6	34
8	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2612-2635.	1.6	60
9	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	9.4	14
10	AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	24
11	Accelerating drug development in breast cancer: New frontiers for ER inhibition. <i>Cancer Treatment Reviews</i> , 2022, 109, 102432.	7.7	28
12	Head-to-Head Evaluation of ¹⁸ F-FES and ¹⁸ F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 326-331.	5.0	69
13	Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 113-120.	3.0	4
14	Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. <i>Molecular Cell</i> , 2021, 81, 708-723.e5.	9.7	51
15	Unlocking the potential of antibody-drug conjugates for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 327-344.	27.6	498
16	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K± Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.9	20
17	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 44.	5.2	11
18	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	5.2	16

#	ARTICLE	IF	CITATIONS
19	Independent real-world application of a clinical-grade automated prostate cancer detection system. <i>Journal of Pathology</i> , 2021, 254, 147-158.	4.5	57
20	Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1559-1570.	3.4	6
21	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i> -Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	7.0	15
22	Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752.	2.8	17
23	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
24	Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	13
25	Mutant SF3B1 promotes AKT- and NF- κ B-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	22
26	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. <i>JCO Precision Oncology</i> , 2021, 5, 6-16.	3.0	2
27	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	3.4	10
28	HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. <i>Nature Communications</i> , 2021, 12, 6667.	12.8	47
29	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	7.1	66
30	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	2.9	19
31	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1217-1223.	3.0	1
32	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	5.2	27
33	Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. <i>Annals of Oncology</i> , 2020, 31, 991-1000.	1.2	17
34	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. <i>Genome Medicine</i> , 2020, 12, 78.	8.2	10
35	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207052.	2.0	5
36	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹ Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020, 296, 370-378.	7.3	40

#	ARTICLE	IF	CITATIONS
37	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
38	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	13.2	96
39	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	7.0	54
40	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
41	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7575-7582.	6.4	127
42	Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. <i>Breast Cancer Research</i> , 2019, 21, 82.	5.0	35
43	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
44	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K inhibitors. <i>Science</i> , 2019, 366, 714-723.	12.6	185
45	Reversible histone glycation is associated with disease-related changes in chromatin architecture. <i>Nature Communications</i> , 2019, 10, 1289.	12.8	123
46	Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1148-1150.	1.6	17
47	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87.	5.5	10
48	Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1009-1009.	1.6	13
49	ESR1 and endocrine therapy resistance: more than just mutations. <i>Annals of Oncology</i> , 2018, 29, 787-789.	1.2	10
50	Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. <i>Nature Reviews Cancer</i> , 2018, 18, 377-388.	28.4	148
51	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
52	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	1.6	93
53	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2736-2740.	1.6	141
54	Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. <i>ACS Chemical Biology</i> , 2018, 13, 3374-3384.	3.4	8

#	ARTICLE	IF	CITATIONS
55	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	16.8	307
56	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	3.6	53
57	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
58	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
59	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER β enhancer function. <i>Oncogene</i> , 2018, 37, 4692-4710.	5.9	102
60	New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 803-808.	2.8	47
61	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	12.8	105
62	Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1226-1235.	0.5	15
63	The SERM/SERD basedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. <i>ELife</i> , 2018, 7, .	6.0	72
64	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2 ⁺ advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017, 116, 726-730.	6.4	112
65	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. <i>OncImmunology</i> , 2017, 6, e1267891.	4.6	66
66	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. <i>Cancer Discovery</i> , 2017, 7, 277-287.	9.4	286
67	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
68	Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. <i>Oncogene</i> , 2017, 36, 2255-2264.	5.9	283
69	AKT Inhibition in Solid Tumors With AKT1 Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	1.6	240
70	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
71	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. <i>ELife</i> , 2016, 5, .	6.0	212
72	Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 91-97.	2.5	33

#	ARTICLE	IF	CITATIONS
73	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , 2016, 27, 1443-1448.	1.2	79
74	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹ Zr-Trastuzumab PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1523-1528.	5.0	146
75	Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1310.	7.1	395
76	PK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242.	16.8	187
77	Resistance to PI3K Pathway Inhibition. <i>Cancer Drug Discovery and Development</i> , 2016, , 125-147.	0.4	2
78	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	12.4	276
79	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015, 47, 1212-1219.	21.4	139
80	Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 313ra182.	12.4	460
81	Feedback Suppression of PI3K Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K ² . <i>Cancer Cell</i> , 2015, 27, 109-122.	16.8	203
82	Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling. <i>Cancer Discovery</i> , 2014, 4, 334-347.	9.4	169
83	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	2.4	91
84	PTEN is a protein tyrosine phosphatase for IRS1. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 522-527.	8.2	116
85	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor -Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	1.6	165
86	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor -Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	1.6	303
87	<i>ESR1</i> ligand-binding domain mutations in hormone-resistant breast cancer. <i>Nature Genetics</i> , 2013, 45, 1439-1445.	21.4	960
88	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. <i>Cancer Cell</i> , 2012, 22, 668-682.	16.8	469
89	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6784-6791.	7.0	176
90	Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer. <i>Cancer Discovery</i> , 2012, 2, 311-319.	9.4	188

#	ARTICLE	IF	CITATIONS
91	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 2011, 11, 263-275.	2.4	368
92	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.	5.9	471
93	AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell, 2011, 19, 58-71.	16.8	867
94	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell, 2011, 19, 575-586.	16.8	1,026
95	mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery, 2011, 1, 248-259.	9.4	385
96	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	7.1	291
97	Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene, 2010, 29, 325-334.	5.9	106
98	SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers. Clinical Cancer Research, 2008, 14, 240-248.	7.0	175
99	Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling. PLoS ONE, 2008, 3, e3065.	2.5	248